Form 4: Natera Co-Founder Jonathan Sheena Executes Stock Sale
Statement of Changes in Beneficial Ownership
Natera Co-Founder Jonathan Sheena sold 107 shares of common stock to satisfy tax obligations related to RSU vesting.
Summary
- Jonathan Sheena, Co-Founder and Director of Natera, Inc., sold 107 shares of common stock on May 1, 2026.
- The shares were sold at a price of $206.16 per share.
- The transaction was executed to cover tax withholding obligations resulting from the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Sheena maintains direct ownership of 255,652 shares.
- The sale was conducted under a pre-arranged Rule 10b5-1(c) trading plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a strategic divestment.
Positives
- The transaction was purely administrative, intended to satisfy tax liabilities rather than reflecting a change in investment sentiment.
- The sale was executed under a pre-established Rule 10b5-1 trading plan, indicating compliance with corporate governance standards.
Negatives
- The filing represents a reduction in the direct equity stake held by a company co-founder.
Risks
- Reliance on equity-based compensation for key personnel can lead to periodic selling pressure as tax obligations arise.
Future Outlook
No forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling for tax purposes is a standard practice in the biotechnology sector, where equity compensation is a significant component of executive remuneration.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to manage stock sales while avoiding potential insider trading concerns.
- The volume of shares sold (107) is negligible relative to the total holdings of the reporting person.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan | Execution of a sale under a Rule 10b5-1(c) plan. | 05/01/2026 | Ensures regulatory compliance and transparency regarding insider transactions. |
Related Party Transactions
- The reporting person maintains indirect ownership of 20,282 shares through Caraluna 1 Trust and 20,282 shares through Caraluna 2 Trust.
Stakeholder Impact
- Minimal impact on shareholders as the transaction size is immaterial to the company's total outstanding shares.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Grant date of the Stock Unit Agreement. |
| 04/30/2026 | Acquisition of 48 shares under the Employee Stock Purchase Plan. |
| 05/01/2026 | Date of the reported stock sale transaction. |
| 05/05/2026 | Date of filing. |
Keywords
Natera, NTRA, Insider Trading, Form 4, Equity Compensation, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.